|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAB27A |
Gene summary for RAB27A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAB27A | Gene ID | 5873 |
| Gene name | RAB27A, member RAS oncogene family | |
| Gene Alias | GS2 | |
| Cytomap | 15q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | A2RU94 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5873 | RAB27A | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 4.09e-04 | 8.35e-01 | -0.0263 |
| 5873 | RAB27A | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 3.85e-08 | 5.85e-02 | -0.0166 |
| 5873 | RAB27A | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.91e-15 | 2.20e-01 | -0.0132 |
| 5873 | RAB27A | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.97e-21 | 2.10e-01 | -0.013 |
| 5873 | RAB27A | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 4.83e-07 | 1.14e-01 | -0.0121 |
| 5873 | RAB27A | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.32e-02 | 3.19e-01 | -0.0822 |
| 5873 | RAB27A | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.01e-04 | 3.88e-01 | -0.0809 |
| 5873 | RAB27A | C04 | Human | Oral cavity | OSCC | 1.23e-10 | 5.30e-01 | 0.2633 |
| 5873 | RAB27A | C21 | Human | Oral cavity | OSCC | 2.46e-41 | 1.11e+00 | 0.2678 |
| 5873 | RAB27A | C30 | Human | Oral cavity | OSCC | 1.03e-27 | 1.22e+00 | 0.3055 |
| 5873 | RAB27A | C38 | Human | Oral cavity | OSCC | 5.70e-03 | 8.53e-01 | 0.172 |
| 5873 | RAB27A | C43 | Human | Oral cavity | OSCC | 4.64e-05 | 2.22e-01 | 0.1704 |
| 5873 | RAB27A | C46 | Human | Oral cavity | OSCC | 1.04e-11 | 3.24e-01 | 0.1673 |
| 5873 | RAB27A | C51 | Human | Oral cavity | OSCC | 2.99e-08 | 3.33e-01 | 0.2674 |
| 5873 | RAB27A | C57 | Human | Oral cavity | OSCC | 6.52e-10 | 3.80e-01 | 0.1679 |
| 5873 | RAB27A | C06 | Human | Oral cavity | OSCC | 1.66e-02 | 7.66e-01 | 0.2699 |
| 5873 | RAB27A | C08 | Human | Oral cavity | OSCC | 8.98e-13 | 4.08e-01 | 0.1919 |
| 5873 | RAB27A | C09 | Human | Oral cavity | OSCC | 1.22e-04 | 8.69e-02 | 0.1431 |
| 5873 | RAB27A | LN22 | Human | Oral cavity | OSCC | 4.80e-08 | 8.42e-01 | 0.1733 |
| 5873 | RAB27A | LN46 | Human | Oral cavity | OSCC | 2.16e-08 | 4.57e-01 | 0.1666 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
| GO:1990182 | Colorectum | AD | exosomal secretion | 16/3918 | 20/18723 | 2.67e-08 | 1.47e-06 | 16 |
| GO:0097734 | Colorectum | AD | extracellular exosome biogenesis | 16/3918 | 21/18723 | 9.02e-08 | 4.52e-06 | 16 |
| GO:0006605 | Colorectum | AD | protein targeting | 105/3918 | 314/18723 | 1.39e-07 | 6.44e-06 | 105 |
| GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
| GO:0140112 | Colorectum | AD | extracellular vesicle biogenesis | 16/3918 | 23/18723 | 7.04e-07 | 2.49e-05 | 16 |
| GO:0042060 | Colorectum | AD | wound healing | 128/3918 | 422/18723 | 2.73e-06 | 7.89e-05 | 128 |
| GO:0051650 | Colorectum | AD | establishment of vesicle localization | 57/3918 | 161/18723 | 1.47e-05 | 3.15e-04 | 57 |
| GO:0036257 | Colorectum | AD | multivesicular body organization | 17/3918 | 31/18723 | 3.45e-05 | 6.29e-04 | 17 |
| GO:0071985 | Colorectum | AD | multivesicular body sorting pathway | 19/3918 | 37/18723 | 4.08e-05 | 7.26e-04 | 19 |
| GO:0007032 | Colorectum | AD | endosome organization | 33/3918 | 82/18723 | 5.30e-05 | 9.01e-04 | 33 |
| GO:0051648 | Colorectum | AD | vesicle localization | 59/3918 | 177/18723 | 7.83e-05 | 1.25e-03 | 59 |
| GO:0045921 | Colorectum | AD | positive regulation of exocytosis | 33/3918 | 86/18723 | 1.58e-04 | 2.20e-03 | 33 |
| GO:0050878 | Colorectum | AD | regulation of body fluid levels | 108/3918 | 379/18723 | 2.54e-04 | 3.20e-03 | 108 |
| GO:0072593 | Colorectum | AD | reactive oxygen species metabolic process | 73/3918 | 239/18723 | 2.79e-04 | 3.42e-03 | 73 |
| GO:0051047 | Colorectum | AD | positive regulation of secretion | 90/3918 | 310/18723 | 4.11e-04 | 4.66e-03 | 90 |
| GO:2000379 | Colorectum | AD | positive regulation of reactive oxygen species metabolic process | 29/3918 | 76/18723 | 4.31e-04 | 4.82e-03 | 29 |
| GO:1903532 | Colorectum | AD | positive regulation of secretion by cell | 82/3918 | 282/18723 | 6.85e-04 | 7.00e-03 | 82 |
| GO:0006887 | Colorectum | AD | exocytosis | 96/3918 | 352/18723 | 2.48e-03 | 1.90e-02 | 96 |
| GO:2000377 | Colorectum | AD | regulation of reactive oxygen species metabolic process | 48/3918 | 157/18723 | 2.77e-03 | 2.09e-02 | 48 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAB27A | SNV | Missense_Mutation | c.610N>T | p.His204Tyr | p.H204Y | P51159 | protein_coding | tolerated(0.05) | benign(0.009) | TCGA-E9-A1N8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| RAB27A | SNV | Missense_Mutation | c.599N>A | p.Arg200Gln | p.R200Q | P51159 | protein_coding | tolerated(0.64) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RAB27A | SNV | Missense_Mutation | c.188G>A | p.Gly63Asp | p.G63D | P51159 | protein_coding | deleterious(0.01) | benign(0.1) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RAB27A | SNV | Missense_Mutation | c.520A>C | p.Ile174Leu | p.I174L | P51159 | protein_coding | deleterious(0.04) | benign(0.04) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| RAB27A | SNV | Missense_Mutation | c.112N>C | p.Phe38Leu | p.F38L | P51159 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RAB27A | deletion | Frame_Shift_Del | c.297delN | p.Phe99LeufsTer3 | p.F99Lfs*3 | P51159 | protein_coding | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| RAB27A | SNV | Missense_Mutation | c.502N>G | p.Thr168Ala | p.T168A | P51159 | protein_coding | tolerated(0.7) | benign(0) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAB27A | SNV | Missense_Mutation | c.642N>T | p.Lys214Asn | p.K214N | P51159 | protein_coding | tolerated(0.3) | benign(0.013) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAB27A | SNV | Missense_Mutation | novel | c.13G>T | p.Asp5Tyr | p.D5Y | P51159 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| RAB27A | SNV | Missense_Mutation | novel | c.271N>T | p.Asp91Tyr | p.D91Y | P51159 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5873 | RAB27A | ENZYME | inhibitor | 328083519 | ||
| 5873 | RAB27A | ENZYME | emapalumab | EMAPALUMAB | ||
| 5873 | RAB27A | ENZYME | Emapalumab-lzsg | EMAPALUMAB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |